This story below is great. You can find the rest of the article on Zoomed In.
I’m in the ACT Stem Cell Trial for Stargardt Disease!
iMy last article highlighted my experience at the Visions 2012 conference and the closing session’s three main speakers. They spoke about some of the ongoing human clinical trials exhibiting great promise for battling retinal degenerative diseases. One of those speakers, Matthew Vincent, Director of Business Development at Advanced Cell Technology (ACT), spoke effectively about the current stem cell trials for both Stargardt disease and AMD. And even more recently, ACT announced that they treated their fourth Stargardt patient, the first patient to receive a higher RPE cell concentration in their worst eye. I am excited to inform you that I am this patient! I was treated on July 11th at Wills Eye Institute in Philadelphia. It was an exciting experience that I’ll never forget; physically joining the team within the many teams that have worked so hard to bring us to this point in medical history
Geron is down again closing at $1.65 on 800,758 shares. The three month avg. is 712,632 shares. Waiting for results in Dec 2012.
AAPL, I was feeling great pre-market. AAPL $6+ should have sold. Closed down $3.95 at $616.81.
Good luck in this rigged casino,
Geron is down again closing at $1.65 on 800,758 shares. The three month avg. is 712,632 shares. Waiting for results in Dec 2012.
AAPL, I was feeling great pre-market. AAPL $6+ should have sold. Closed down $3.95 at $616.81.
Good luck in this rigged casino,
No comments:
Post a Comment